

Jeanne Palmer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3441649/publications.pdf>

Version: 2024-02-01

59
papers

1,978
citations

257450

24
h-index

265206

42
g-index

59
all docs

59
docs citations

59
times ranked

2790
citing authors

#	ARTICLE	IF	CITATIONS
1	Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1863-1869.	2.0	342
2	Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 710-716.	2.0	151
3	Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1247-1256.	2.0	139
4	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
5	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
6	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2017, 3, 936.	7.1	90
7	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	3.5	77
8	Pulmonary Symptoms Measured by the National Institutes of Health Lung Score Predict Overall Survival, Nonrelapse Mortality, and Patient-Reported Outcomes In Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 337-344.	2.0	76
9	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	7.0	68
10	Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. <i>Annals of the American Thoracic Society</i> , 2016, 13, 1932-1939.	3.2	67
11	Impact of Age on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1341-1348.	2.0	52
12	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	1.4	52
13	Assessment of Joint and Fascia Manifestations in Chronic Graft-versus-Host Disease. <i>Arthritis and Rheumatology</i> , 2014, 66, 1044-1052.	5.6	50
14	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
15	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , 2018, 132, 686-686.	1.4	44
16	Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 557-569.	1.8	44
17	Analysis of Gastrointestinal and Hepatic Chronic Graft-versus-Host Disease Manifestations on Major Outcomes: A Chronic Graft-versus-Host Disease Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 784-791.	2.0	43
18	Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 160-166.	1.4	43

#	ARTICLE	IF	CITATIONS
19	Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 204-211.	2.4	41
20	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38
21	Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 967-972.	2.0	34
22	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
23	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	3.5	29
24	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 49.	6.2	28
25	High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 239-247.	2.0	27
26	Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 728-733.	2.0	25
27	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
28	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Blood Cancer Journal</i> , 2020, 10, 36.	6.2	14
29	Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2020, 61, 1996-2002.	1.3	9
30	Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 398-402.	2.0	8
31	Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2267-2273.	2.0	7
32	Does early chimerism testing predict outcomes after allogeneic hematopoietic stem cell transplantation?. <i>Leukemia and Lymphoma</i> , 2021, 62, 252-254.	1.3	5
33	Transplantation in Myelofibrosis Reaches the Molecular Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1043-1044.	2.0	4
34	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
35	The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092520.	2.5	4
36	Quality of Life in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 375-390.	2.2	4

#	ARTICLE	IF	CITATIONS
37	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. American Journal of Hematology, 2017, 92, E626-E627.	4.1	3
38	Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. Journal of Hematology (Brossard, Quebec), 2021, 10, 207-211.	1.0	3
39	Early Detection is Key: Is Handheld Spirometry the Answer?. Biology of Blood and Marrow Transplantation, 2016, 22, 780-781.	2.0	2
40	Clinical Benefit of Ropoginterferon Alfa 2b (P1101) in Patients with Myelofibrosis. Blood, 2018, 132, 5475-5475.	1.4	2
41	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. Blood, 2018, 132, 4289-4289.	1.4	1
42	Polycythemia secondary to renal cysts. Journal of Nephrology, 2022, 35, 1743-1746.	2.0	1
43	Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?. Leukemia and Lymphoma, 2019, 60, 2034-2041.	1.3	0
44	Patterns of Serum Free Light Chain (FLC) Recovery After Reduced Intensity Conditioning (RIC) Allogeneic Transplant for Multiple Myeloma (MM) Predict Long Term Outcomes. Blood, 2010, 116, 1301-1301.	1.4	0
45	Bortezomib Based Therapy for Newly Diagnosed Patients with Advanced Multisystem Light Chain Amyloidosis (AL). Blood, 2011, 118, 1880-1880.	1.4	0
46	Patterns of Myeloma (MM) Progression After Autologous Transplant (AHCT) – Biochemical Progression Vs. Clinical Relapse. Blood, 2011, 118, 5097-5097.	1.4	0
47	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. Blood, 2012, 120, 1940-1940.	1.4	0
48	Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes. Blood, 2012, 120, 467-467.	1.4	0
49	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	1.4	0
50	Influence Of Organ Scores On Mortality In Chronic GVHD: Results From The Chronic GVHD Consortium. Blood, 2013, 122, 4614-4614.	1.4	0
51	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	1.4	0
52	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. Blood, 2018, 132, 1443-1443.	1.4	0
53	Does Early T Cell Chimerism Predict Outcomes after Allogeneic Hematopoietic Cell Transplantation ?. Blood, 2018, 132, 3360-3360.	1.4	0
54	Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group. Blood, 2018, 132, 4297-4297.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Addressing the Adequacy of Current MPN Pain Management Strategies: An International Survey of 502 Patients By the MPN Quality of Life Study Group. Blood, 2018, 132, 4298-4298.	1.4	0
56	Assessment of Quality of Life Following Allogeneic Stem Cell Transplant for Myelofibrosis. Blood, 2018, 132, 4827-4827.	1.4	0
57	Tobacco Use in the Myeloproliferative Neoplasms: Patient Behavior, Opinions, and Care. Blood, 2018, 132, 5846-5846.	1.4	0
58	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. Blood, 2018, 132, 2678-2678.	1.4	0
59	Clinical Outcomes of Matched Unrelated Allogeneic Stem Cell Transplant Patients: Low Dose ATG Vs. No ATG. Blood, 2018, 132, 5715-5715.	1.4	0